Evaluation of tedizolid againstStaphylococcus aureusand enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid

Results of the Surveillance of Tedizolid Activity and Resistance Program: in vitro susceptibility of Gram-positive pathogens collected in 2011 and 2012 from the United States and Europe

(2015) Daniel F. Sahm et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial

(2014) Gregory J Moran et al.   LANCET INFECTIOUS DISEASES

Tedizolid Phosphate vs Linezolid for Treatment of Acute Bacterial Skin and Skin Structure Infections

(2013) Philippe Prokocimer et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

The Clinical Significance of Vancomycin Minimum Inhibitory Concentration in Staphylococcus aureus Infections: A Systematic Review and Meta-analysis

(2012) S. J. van Hal et al.   CLINICAL INFECTIOUS DISEASES

Antimicrobial-Resistant Pathogens Associated with Healthcare-Associated Infections Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009–2010

(2012) Dawn M. Sievert et al.   INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY

In vitro activity of tedizolid (TR-700) against linezolid-resistant staphylococci

(2011) I. Rodriguez-Avial et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Comparative In Vitro Antimicrobial Activities of Torezolid (TR-700), the Active Moiety of a New Oxazolidinone, Torezolid Phosphate (TR-701), Determination of Tentative Disk Diffusion Interpretive Criteria, and Quality Control Ranges

(2010) S. D. Brown et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Daptomycin Nonsusceptible Enterococci: An Emerging Challenge for Clinicians

(2010) T. Kelesidis et al.   CLINICAL INFECTIOUS DISEASES

In Vitro Activity of TR-700, the Active Ingredient of the Antibacterial Prodrug TR-701, a Novel Oxazolidinone Antibacterial Agent

(2009) R. Schaadt et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Activity of oxazolidinone TR-700 against linezolid-susceptible and -resistant staphylococci and enterococci

(2009) D. M. Livermore et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Occurrence of vancomycin-tolerant and heterogeneous vancomycin-intermediate strains (hVISA) among Staphylococcus aureus causing bloodstream infections in nine USA hospitals

(2009) H. S. Sader et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Heterogeneous Vancomycin‐Intermediate Susceptibility Phenotype in Bloodstream Methicillin‐ResistantStaphylococcus aureusIsolates from an International Cohort of Patients with Infective Endocarditis: Prevalence, Genotype, and Clinical Significance

(2009) In‐Gyu Bae et al.   JOURNAL OF INFECTIOUS DISEASES

In Vitro Activity of TR-700, the Antibacterial Moiety of the Prodrug TR-701, against Linezolid-Resistant Strains

(2008) K. J. Shaw et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY